摘要
目的探索冷冻治疗IV期非小细胞肺癌引起的血清CEA的变化与病理类型（鳞癌，腺癌）和治疗方法的相关性及对总生存时间的预测性。方法回顾性分析2005年10月～2011年4月间88例IV期非小细胞肺癌患者冷冻消融前后的CEA改变及总生存时间。其中62例行综合冷冻消融，26例行姑息冷冻消融。结果冷冻消融显著降低肺腺癌患者的CEA水平，但对于鳞癌则否。腺癌患者中，冷冻导致的CEA水平下降在综合治疗的患者中显著高于姑息治疗的患者。经过综合冷冻消融治疗患者的总生存期较姑息冷冻治疗的患者延长，在接受冷冻治疗的腺癌患者中，术前CEA正常的总生存显著高于术前CEA异常者。结论在非小细胞肺癌患者中，术前CEA水平及冷冻治疗后CEA水平的变化可以做为冷冻治疗效果及总生存时间的很好的预后指标。
Objective Determined whether cryoablation- induced changes in serum CEA levels correlated with tumor type （ adenocarcinoma or squamous carcinoma） and treatment type （ comprehensive therapy or palliative therapy） in patients with metastatic NSCLC, and assessed whether pre - treatment CEA levels predicted overall survival （OS） time. Methods We retrospectively reviewed the clinical data of 79 patients with metastatic NSCLC who underwent comprehensive （58 patients） or palliative （21 patients） therapy. Pre -and post- cryoablation serum CEA levels and overall survival time were determined for all patients. Results Cryoablation significantly reduced CEA lev- els in adenocarcinoma, but not squamous carcinoma, patients. Among adenocarcinoma patients, the cryoablation - induced reduction in CEA levels was significantly greater after comprehensive treatment than after palliative treatment ; the OS of patients under comprehensive cryoablation was longer than those under palliative treatment. Among adeno- carcinoma patients receiving comprehensive cryoablation, OS was significantly longer in those with normal pre - treat- ment serum CEA levels than in those with abnormal pre - treatment serum CEA levels. Conclusion Pretreatment lev- el and change of serum CEA can be a good indicator for therapeutic effects and OS in metastatic NSCLC patients un- der percutaneous cryosurgery.
出处
《现代医院》
2014年第4期7-10,14,共5页
Modern Hospitals
基金
广东省医学科研基金(编号A2012467)
